Saphnelo (anifrolumab-fnia) Patient Assistance Program
Don’t let the high cost of brand type I interferon receptor antagonist disrupt your systemic lupus treatment. We help eligible patients access Saphnelo (anifrolumab-fnia IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Saphnelo (anifrolumab-fnia) is FDA-approved for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. First-in-class type I interferon receptor subunit 1 (IFNAR1) monoclonal antibody antagonist — blocks type I IFN signaling, a central driver of SLE pathophysiology.
- Without assistance, Saphnelo costs commonly run approximately $6,000–$8,000 per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Saphnelo for a flat $69.95 per month.
- Other SLE therapies: hydroxychloroquine (Plaquenil generic — foundation therapy), corticosteroids (methylprednisolone, prednisone), immunosuppressants (mycophenolate — CellCept generic, azathioprine, methotrexate, cyclophosphamide), biologics (Benlysta — belimumab, IV/SC; Lupkynis — voclosporin oral for lupus nephritis; rituximab off-label). Newer: CAR-T (Kymriah and others in SLE trials). SLE patients often on multiple therapies. Lupus Foundation of America and Lupus Research Alliance provide patient resources. Rheumatology consultation essential.
What is Saphnelo Prescription Assistance Program?
The Saphnelo Patient Assistance Program helps eligible patients access this type I IFN receptor antagonist at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Saphnelo PAP enrollment for a flat $69.95 per month — so you never face a gap in Saphnelo SLE therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Saphnelo enrollment — so you never face a gap in your systemic lupus treatment.
Pharmacy Price Comparison
- Without assistance, Saphnelo costs thousands per infusion. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Hydroxychloroquine generic | ~$15/mo | Cheap generic SLE foundation |
| Rheumatology infusion center | ~$7,500/infusion | Save substantially |
| Community rheumatology | ~$7,000/infusion | Save substantially |
| Hospital outpatient | ~$8,000/infusion | Save substantially |
| 340B-eligible institution | ~$6,000/infusion | Save substantially |
| Benlysta IV (alt biologic) | ~$4,000/infusion | Alt SLE biologic |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Saphnelo — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Saphnelo Prescription Program?
The Saphnelo Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Hydroxychloroquine (generic) is foundation SLE therapy. Biologics (Benlysta, Saphnelo, and Lupkynis for LN) transformed SLE management. Rheumatology consultation and comprehensive SLE care planning essential.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Saphnelo assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Saphnelo is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Saphnelo:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $6,000–$8,000/infusion per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Saphnelo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Saphnelo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Saphnelo:
Saphnelo is the first type I interferon receptor antagonist for SLE — blocks IFNAR1 (subunit 1 of the type I interferon receptor). Type I IFNs (IFN-alpha and IFN-beta) drive much of SLE pathophysiology — patients with elevated ‘IFN signature’ benefit particularly. Novel mechanism complementary to other SLE biologics.
How It Works:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems — skin, joints, kidneys, heart, lungs, blood cells, nervous system. Complex pathophysiology involves autoantibodies, immune complexes, and dysregulated immune signaling. Type I interferons (particularly IFN-alpha) are central pathogenic mediators in most SLE patients — the ‘IFN signature.’ Anifrolumab is a monoclonal antibody that binds the type I interferon receptor subunit 1 (IFNAR1) — blocks binding of all type I interferons (multiple IFN-alpha subtypes, IFN-beta, IFN-omega, IFN-kappa) — comprehensive type I IFN blockade. Reduces SLE disease activity and glucocorticoid requirements in trials (TULIP-1, TULIP-2). Distinct mechanism from Benlysta (belimumab — anti-BAFF/BLyS antibody depleting mature B-cells) and other SLE therapies. Complementary options.
Form and Use:
Saphnelo 300 mg IV every 4 weeks. Given at rheumatology infusion center. Standard SLE therapy (hydroxychloroquine, corticosteroids, immunosuppressants) generally continued. Rheumatology follow-up.
Generic Availability:
No generic Saphnelo. Other SLE biologics: Benlysta (belimumab — brand; IV or SC for SLE and lupus nephritis; anti-BAFF/BLyS antibody). Lupkynis (voclosporin — brand oral calcineurin inhibitor for lupus nephritis). Foundational SLE therapy (generic): hydroxychloroquine (Plaquenil generic), corticosteroids (methylprednisolone, prednisone), immunosuppressants (mycophenolate/CellCept generic, azathioprine generic, methotrexate generic, cyclophosphamide). Rituximab and biosimilars off-label for SLE. Newer: CAR-T in SLE trials (Kymriah and others). Lupus Foundation of America and Lupus Research Alliance provide patient support and research advocacy.
Warnings:
Serious infections (increased herpes zoster, upper and lower respiratory infections — assess infection status before starting; consider herpes zoster vaccination), hypersensitivity reactions including anaphylaxis, malignancy risk (theoretical with immunomodulators), embryo-fetal considerations. Other: nasopharyngitis, upper respiratory infections, bronchitis, cough, hypersensitivity reactions, infusion reactions. Rheumatology follow-up for SLE disease activity monitoring and immunosuppression coordination.
FAQ (Frequently Asked Questions)
How much does Saphnelo cost without insurance?
$6,000–$8,000 per infusion. With every-4-week dosing, monthly cost matches per-infusion. Generic hydroxychloroquine (SLE foundation) costs $15/month. Benlysta (alternative SLE biologic) costs $4,000–$5,000 per IV infusion or ~$1,500–$2,500 per SC injection.
How is Saphnelo different from Benlysta and other SLE biologics?
Different mechanisms. Saphnelo blocks the type I interferon receptor (IFNAR1) — comprehensive type I IFN blockade. Benlysta (belimumab) is anti-BAFF/BLyS — depletes mature B-cells. Lupkynis (voclosporin) is oral calcineurin inhibitor for lupus nephritis. Complementary mechanisms — SLE patients may benefit from different therapies based on disease features and biomarkers.
What is the type I interferon signature in SLE?
Most SLE patients have elevated type I IFN gene expression — the ‘IFN signature’ — reflecting central role of type I IFNs in SLE pathophysiology. Patients with high IFN signature may benefit particularly from IFN-targeted therapy like Saphnelo. Biomarker guidance an emerging area.
Should I continue hydroxychloroquine with Saphnelo?
Yes — hydroxychloroquine (Plaquenil generic) is foundation SLE therapy for essentially all SLE patients. Reduces flares, improves survival, protects against complications. Should be continued alongside Saphnelo unless contraindication (retinopathy, others). Regular ophthalmology screening for retinopathy.
How is lupus nephritis treated?
Lupus nephritis (kidney involvement in SLE) requires specific therapy — mycophenolate (CellCept generic) or cyclophosphamide for induction; mycophenolate or azathioprine for maintenance; Lupkynis (voclosporin) added for many patients; Benlysta approved for lupus nephritis. Nephrology co-management essential.
Take Control of Your Medication Costs
Type I IFN blockade addresses a central SLE mechanism — biologic advocacy access is critical for many patients. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.